Related Experiment Video
Updated: Jan 6, 2026
![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)
An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use
Published on: May 24, 2024
Fosrolapitant/Palonosetron: First Approval.
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Fosrolapitant/palonosetron is approved in China for preventing chemotherapy-induced nausea and vomiting. This fixed-dose combination targets neurokinin-1 and 5-HT3 receptors for effective treatment.
Area of Science:
- Pharmacology
- Oncology supportive care
Background:
- Chemotherapy-induced nausea and vomiting (CINV) remains a significant challenge for patients undergoing cancer treatment.
- Neurokinin-1 (NK-1) receptor antagonists and 5-hydroxytryptamine-3 (5-HT3) receptor antagonists are key classes for managing CINV.
Purpose of the Study:
- To summarize the development milestones of fosrolapitant/palonosetron (Ritanine®).
- To highlight the drug's first approval for preventing CINV in China.
Main Methods:
- Review of preclinical and clinical development data for fosrolapitant/palonosetron.
- Analysis of regulatory submission and approval process in China.
Main Results:
- Fosrolapitant, a novel NK-1 receptor antagonist prodrug, and palonosetron, a second-generation 5-HT3 receptor antagonist, form a fixed-dose combination.
- On May 29, 2025, fosrolapitant/palonosetron received its first marketing approval in China.
- The approval is for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy in adults.
Conclusions:
- Fosrolapitant/palonosetron represents a significant advancement in CINV management.
- The approval in China marks a crucial milestone for this novel fixed-dose combination therapy.
More Related Videos
10:13Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs
Published on: November 8, 2024
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
Related Concept Videos
FDA Approved Drugs: Changes to Approved Drugs
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...